TW202128184A - 酒精性肝炎之治療 - Google Patents

酒精性肝炎之治療 Download PDF

Info

Publication number
TW202128184A
TW202128184A TW109133945A TW109133945A TW202128184A TW 202128184 A TW202128184 A TW 202128184A TW 109133945 A TW109133945 A TW 109133945A TW 109133945 A TW109133945 A TW 109133945A TW 202128184 A TW202128184 A TW 202128184A
Authority
TW
Taiwan
Prior art keywords
25hc3s
salt
dose
score
administered
Prior art date
Application number
TW109133945A
Other languages
English (en)
Chinese (zh)
Inventor
偉琦 林
詹姆士 布朗
泰倫斯 布萊斯克
Original Assignee
美商杜瑞克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商杜瑞克公司 filed Critical 美商杜瑞克公司
Publication of TW202128184A publication Critical patent/TW202128184A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109133945A 2019-09-30 2020-09-29 酒精性肝炎之治療 TW202128184A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US62/908,465 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US62/933,206 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US63/060,564 2020-08-03
US202063081208P 2020-09-21 2020-09-21
US63/081,208 2020-09-21

Publications (1)

Publication Number Publication Date
TW202128184A true TW202128184A (zh) 2021-08-01

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109133945A TW202128184A (zh) 2019-09-30 2020-09-29 酒精性肝炎之治療

Country Status (13)

Country Link
US (2) US20220378802A1 (https=)
EP (1) EP4037650A4 (https=)
JP (1) JP7830313B2 (https=)
KR (1) KR20220075329A (https=)
CN (2) CN119868374A (https=)
AU (1) AU2020357818A1 (https=)
BR (1) BR112022005039A2 (https=)
CA (1) CA3155422A1 (https=)
IL (1) IL291287A (https=)
MX (1) MX2022003778A (https=)
PH (1) PH12022550698A1 (https=)
TW (1) TW202128184A (https=)
WO (1) WO2021067297A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) * 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3493810A4 (en) * 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE

Also Published As

Publication number Publication date
JP7830313B2 (ja) 2026-03-16
CA3155422A1 (en) 2021-04-08
BR112022005039A2 (pt) 2022-06-21
AU2020357818A1 (en) 2022-04-14
US20220378802A1 (en) 2022-12-01
CN119868374A (zh) 2025-04-25
PH12022550698A1 (en) 2023-04-03
JP2022549621A (ja) 2022-11-28
CN114555044B (zh) 2025-02-14
CN114555044A (zh) 2022-05-27
EP4037650A4 (en) 2023-10-18
EP4037650A1 (en) 2022-08-10
MX2022003778A (es) 2022-04-25
IL291287A (en) 2022-05-01
WO2021067297A1 (en) 2021-04-08
KR20220075329A (ko) 2022-06-08
US20260102410A1 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
RU2564104C2 (ru) Композиции инсулинов длительного действия
TW202128184A (zh) 酒精性肝炎之治療
CN103974619B (zh) 治疗法布里病的给药方案
JP2020045346A (ja) ポンペ病の処置のための投与計画
US20240239883A1 (en) Methods of treating homologous recombination deficient cancer
US20230181602A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
TWI818168B (zh) 治療眼疾的方法
CN115715192A (zh) 用于治疗或预防血液系统异常和/或相关疾病的包含15-hepe的组合物
US20230181601A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
BR122025021620A2 (pt) Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica
JP2022538210A (ja) 腎機能障害患者における高アンモニア血症の治療
HK40073572B (zh) 酒精性肝炎的治疗
HK40073572A (en) Treatment of alcoholic hepatitis
Tecellioglu et al. Review of the literature on Alport syndrome: A rare cause of nephrotic syndrome
TWI899198B (zh) 包含15-hepe之組成物及治療或預防血液學病症及/或相關疾病之方法
US20260027094A1 (en) Use of pyridone derivative
WO2025101669A1 (en) Treatment of alcohol-associated hepatitis
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
Mellitus Advances in Clinical and Medical Research
Salom et al. Vitamin C Mega Dose vs. Standard Dose in Smokers with Subclinical Hypovitaminosis C, A Controlled Randomised Clinical Trial–a short review.
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
WO2015063602A1 (en) Desmopressin and blood glucose